Hypertrophic Cardiomyopathy Summary

Hypertrophic cardiomyopathy (HCM) is a genetic condition characterized by thickening of the heart muscle, primarily in the septum, which can reduce blood flow to the aorta. This condition affects approximately 1 in 500 individuals and is often diagnosed around age 40. HCM presents in two forms: obstructive and nonobstructive. While many individuals with HCM experience no complications, serious health issues can arise, necessitating regular monitoring and treatment. Symptoms of HCM may include chest pain during exertion, dizziness, shortness of breath, palpitations, and edema. Around 60% of HCM cases are familial, inherited in an autosomal dominant manner, while other cases lack identifiable genetic changes.

Diagnosis of HCM typically involves a patient’s medical history, physical examination, and tests, such as electrocardiograms (ECG) and echocardiograms, which reveal thickening of the heart wall. Additional tests may include blood tests, cardiac MRIs, and genetic testing, with first-degree relatives recommended for screening. The management and treatment of HCM aim to alleviate symptoms and reduce risk, incorporating lifestyle changes, monitoring, and medications, such as beta-blockers and the newer drug mavacamten, which targets HCM symptoms. For obstructive cases, surgical options like septal myectomy or alcohol septal ablation may be considered, along with implantable cardioverter defibrillators (ICDs) for those at higher risk.

The prognosis for individuals with HCM varies by the onset age and the severity of the condition; however, many lead normal lives with a life expectancy similar to those without HCM. While prevention of HCM is not possible, early screening is vital, especially for first-degree relatives. Regular follow-ups are essential for monitoring heart health and effectively managing the condition.

Hypertrophic cardiomyopathy (HCM) is linked to its pathophysiology, as it involves structural and functional abnormalities of the heart muscle. The thickening of the septum impairs efficient blood flow, particularly in obstructive cases. This remodeling results from genetic factors and hemodynamic stress, establishing a connection between the condition and its underlying mechanisms.

Understanding HCM's pathophysiology is pivotal for diagnosis, symptom recognition, and treatment strategies. Tools like electrocardiograms (ECG) and echocardiograms reveal myocardial changes, guiding the clinical approach. It also aids in identifying symptoms such as chest pain and shortness of breath, facilitating early interventions.

Further, recognizing that about 60% of cases are hereditary underscores the need for genetic testing, which helps identify at-risk individuals for early diagnosis and preventive measures. This relevance enhances overall HCM management and underscores the importance of understanding the underlying pathophysiology.